Expression of Class II Human Leukocyte Antigens on Human Endothelial Cells Shows High Interindividual and Intersubclass Heterogeneity.
Journal
Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
21
06
2022
accepted:
12
01
2023
pmc-release:
01
05
2024
medline:
3
5
2023
pubmed:
10
2
2023
entrez:
9
2
2023
Statut:
ppublish
Résumé
Donor-specific antibodies against class II HLA are a major cause of chronic kidney graft rejection. Nonetheless, some patients presenting with these antibodies remain in stable histological and clinical condition. This study describes the use of endothelial colony-forming cell lines to test the hypothesis of the heterogeneous expression of HLA molecules on endothelial cells in humans. Flow cytometry and immunofluorescence staining revealed substantial interindividual and interlocus variability, with HLA-DQ the most variable. Our data suggest that the expression of HLA class II is predicted by locus. The measurement of endothelial expression of HLA class II in the graft could present a novel paradigm in the evaluation of the alloimmune risk in transplantation and certain diseases. HLA antigens are important targets of alloantibodies and allospecific T cells involved in graft rejection. Compared with research into understanding alloantibody development, little is known about the variability in expression of their ligands on endothelial cells. We hypothesized individual variability in the expression of HLA molecules. We generated endothelial colony forming cell lines from human peripheral blood mononuclear cells ( n =39). Flow cytometry and immunofluorescence staining were used to analyze the cells, and we assessed the relationship between HLA-DQ expression and genotype. Two cohorts of kidney transplant recipients were analyzed to correlate HLA-DQ mismatches with the extent of intragraft microvascular injury. Large variability was observed in the expression of HLA class II antigens, not only between individuals but also between subclasses. In particular, HLA-DQ antigens had a low and heterogeneous expression, ranging from 0% to 85% positive cells. On a within-patient basis, this expression was consistent between endothelial cell colonies and antigen-presenting cells. HLA-DQ5 and -DQ6 were associated with higher levels of expression, whereas HLA-DQ7, -DQ8, and -DQ9 with lower. HLA-DQ5 mismatches among kidney transplant recipients were associated with significant increase in graft microvascular. These data challenge the current paradigm that HLA antigens, in particular HLA class II, are a single genetic and post-translational entity. Understanding and assessing the variability in the expression of HLA antigens could have clinical monitoring and treatment applications in transplantation, autoimmune diseases, and oncology.
Sections du résumé
SIGNIFICANCE STATEMENT
Donor-specific antibodies against class II HLA are a major cause of chronic kidney graft rejection. Nonetheless, some patients presenting with these antibodies remain in stable histological and clinical condition. This study describes the use of endothelial colony-forming cell lines to test the hypothesis of the heterogeneous expression of HLA molecules on endothelial cells in humans. Flow cytometry and immunofluorescence staining revealed substantial interindividual and interlocus variability, with HLA-DQ the most variable. Our data suggest that the expression of HLA class II is predicted by locus. The measurement of endothelial expression of HLA class II in the graft could present a novel paradigm in the evaluation of the alloimmune risk in transplantation and certain diseases.
BACKGROUND
HLA antigens are important targets of alloantibodies and allospecific T cells involved in graft rejection. Compared with research into understanding alloantibody development, little is known about the variability in expression of their ligands on endothelial cells. We hypothesized individual variability in the expression of HLA molecules.
METHODS
We generated endothelial colony forming cell lines from human peripheral blood mononuclear cells ( n =39). Flow cytometry and immunofluorescence staining were used to analyze the cells, and we assessed the relationship between HLA-DQ expression and genotype. Two cohorts of kidney transplant recipients were analyzed to correlate HLA-DQ mismatches with the extent of intragraft microvascular injury.
RESULTS
Large variability was observed in the expression of HLA class II antigens, not only between individuals but also between subclasses. In particular, HLA-DQ antigens had a low and heterogeneous expression, ranging from 0% to 85% positive cells. On a within-patient basis, this expression was consistent between endothelial cell colonies and antigen-presenting cells. HLA-DQ5 and -DQ6 were associated with higher levels of expression, whereas HLA-DQ7, -DQ8, and -DQ9 with lower. HLA-DQ5 mismatches among kidney transplant recipients were associated with significant increase in graft microvascular.
CONCLUSION
These data challenge the current paradigm that HLA antigens, in particular HLA class II, are a single genetic and post-translational entity. Understanding and assessing the variability in the expression of HLA antigens could have clinical monitoring and treatment applications in transplantation, autoimmune diseases, and oncology.
Identifiants
pubmed: 36758118
doi: 10.1681/ASN.0000000000000095
pii: 00001751-202305000-00015
pmc: PMC10125628
doi:
Substances chimiques
HLA Antigens
0
HLA-DQ Antigens
0
Isoantibodies
0
Histocompatibility Antigens Class II
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
846-856Subventions
Organisme : CIHR
ID : PCL-134068
Pays : Canada
Organisme : CIHR
ID : PJT-166018
Pays : Canada
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95(3):410–417. doi: 10.1097/tp.0b013e31827d62e3
doi: 10.1097/tp.0b013e31827d62e3
Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–836. doi: 10.1038/nri3084
doi: 10.1038/nri3084
Choo SY. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. 2007;48(1):11–23. doi: 10.3349/ymj.2007.48.1.11
doi: 10.3349/ymj.2007.48.1.11
Le Bas-Bernardet S, Coupel S, Chauveau A, Soulillou JP, Charreau B. Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation. 2004;78(12):1729–1739. doi: 10.1097/01.tp.0000147339.31581.99
doi: 10.1097/01.tp.0000147339.31581.99
Klein J, Sato A. The HLA system. N Engl J Med. 2000;343(10):702–709. doi: 10.1056/nejm200009073431006
doi: 10.1056/nejm200009073431006
Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12(5):1157–1167. doi: 10.1111/j.1600-6143.2012.04013.x
doi: 10.1111/j.1600-6143.2012.04013.x
Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation. 2012;94(2):172–177. doi: 10.1097/tp.0b013e3182543950
doi: 10.1097/tp.0b013e3182543950
Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant. 2007;7(7):1743–1752. doi: 10.1111/j.1600-6143.2007.01836.x
doi: 10.1111/j.1600-6143.2007.01836.x
Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant. 2007;7(4):857–863. doi: 10.1111/j.1600-6143.2006.01699.x
doi: 10.1111/j.1600-6143.2006.01699.x
Béland MA, Lapointe I, Noel R, et al. Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study. Transpl Int. 2017;30(5):502–509. doi: 10.1111/tri.12934
doi: 10.1111/tri.12934
Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–829. doi: 10.1056/nejmoa1604958
doi: 10.1056/nejmoa1604958
Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional Beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88(2):100–108. doi: 10.1093/jnci/88.2.100
doi: 10.1093/jnci/88.2.100
Beland S, Desy O, Bouchard-Boivin F, Gama A, De Serres SA. Endothelial colony forming cells generated from cryopreserved peripheral blood mononuclear cells. Hum Immunol. 2021;82(4):309–314. doi: 10.1016/j.humimm.2021.02.009
doi: 10.1016/j.humimm.2021.02.009
Desy O, Beland S, Vallin P, et al. IL-6 production by monocytes is associated with graft function decline in patients with borderline changes suspicious for acute T-cell-mediated rejection: a pilot study. Transpl Int. 2018;31(1):92–101. doi: 10.1111/tri.13070
doi: 10.1111/tri.13070
Béland S, Vallin P, Desy O, Levesque E, De Serres SA. Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. J Thromb Haemost. 2017;15(5):1020–1031. doi: 10.1111/jth.13661
doi: 10.1111/jth.13661
Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28–41. doi: 10.1111/ajt.14107
doi: 10.1111/ajt.14107
Nuzzolo ER, Capodimonti S, Martini M, et al. Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. Blood Transfus. 2014;12(suppl 1):s367–s374. doi: 10.2450/2013.0042-13
doi: 10.2450/2013.0042-13
Reinisch A, Hofmann NA, Obenauf AC, et al. Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo. Blood. 2009;113(26):6716–6725. doi: 10.1182/blood-2008-09-181362
doi: 10.1182/blood-2008-09-181362
Haraldsen G, Sollid LM, Bakke O, et al. Major histocompatibility complex class II-dependent antigen presentation by human intestinal endothelial cells. Gastroenterology. 1998;114(4):649–656. doi: 10.1016/s0016-5085(98)70578-5
doi: 10.1016/s0016-5085(98)70578-5
Manyak CL, Tse H, Fischer P, Coker L, Sigal NH, Koo GC. Regulation of class II MHC molecules on human endothelial cells. Effects of IFN and dexamethasone. J Immunol. 1988;140(11):3817–3821. doi: 10.4049/jimmunol.140.11.3817
doi: 10.4049/jimmunol.140.11.3817
Geppert TD, Lipsky PE. Antigen presentation by interferon-gamma-treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression. J Immunol. 1985;135(6):3750–3762. doi: 10.4049/jimmunol.135.6.3750
doi: 10.4049/jimmunol.135.6.3750
Leeaphorn N, Pena JRA, Thamcharoen N, Khankin EV, Pavlakis M, Cardarelli F. HLA-DQ mismatching and kidney transplant outcomes. Clin J Am Soc Nephrol. 2018;13(5):763–771. doi: 10.2215/CJN.10860917
doi: 10.2215/CJN.10860917
Hiltbold EM, Roche PA. Trafficking of MHC class II molecules in the late secretory pathway. Curr Opin Immunol. 2002;14(1):30–35. doi: 10.1016/s0952-7915(01)00295-3
doi: 10.1016/s0952-7915(01)00295-3
Carey BS, Poulton KV, Poles A. Factors affecting HLA expression: a review. Int J Immunogenet. 2019;46(5):307–320. doi: 10.1111/iji.12443
doi: 10.1111/iji.12443
Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol. 2005;5(10):793–806. doi: 10.1038/nri1708
doi: 10.1038/nri1708
van Lith M, McEwen-Smith RM, Benham AM. HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM. J Biol Chem. 2010;285(52):40800–40808. doi: 10.1074/jbc.m110.148155
doi: 10.1074/jbc.m110.148155
Wubbolts R, Neefjes J. Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors. Immunol Rev. 1999;172(1):189–208. doi: 10.1111/j.1600-065x.1999.tb01366.x
doi: 10.1111/j.1600-065x.1999.tb01366.x
Unanue ER, Turk V, Neefjes J. Variations in MHC class II antigen processing and presentation in health and disease. Annu Rev Immunol. 2016;34(1):265–297. doi: 10.1146/annurev-immunol-041015-055420
doi: 10.1146/annurev-immunol-041015-055420
Singh P, Goode T, Dean A, Awad SS, Darlington GJ. Elevated interferon gamma signaling contributes to impaired regeneration in the aged liver. J Gerontol Ser A. 2011;66A(9):944–956. doi: 10.1093/gerona/glr094
doi: 10.1093/gerona/glr094
Varma TK, Lin CY, Toliver-Kinsky TE, Sherwood ER. Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors. Clin Vaccin Immunol. 2002;9(3):530–543. doi: 10.1128/cdli.9.3.530-543.2002
doi: 10.1128/cdli.9.3.530-543.2002
Wedgwood JF, Hatam L, Bonagura VR. Effect of interferon-gamma and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical vein endothelial cells. Cell Immunol. 1988;111(1):1–9. doi: 10.1016/0008-8749(88)90046-9
doi: 10.1016/0008-8749(88)90046-9